Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Does bridging therapy affect lymphoma CAR-T outcomes?

Michael Jain • 8 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T

Whether bridging therapy affects the outcomes of patients with lymphoma who receive CAR-T is unknown. Here, Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, explains the characteristics and outcomes of large B-cell lymphoma patients receiving bridging therapy while awaiting axicabtagene ciloleucel therapy from the US Lymphoma CAR T Consortium analysis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Michael Jain

1:11
ZUMA-11 study overview: axi-cel plus utomilumab in R/R DLBCL
Michael Jain • 8 Dec 2019
2:13
Lymphoma tumor microenvironment influences toxicity after CD19 CAR-T
Michael Jain • 7 Dec 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals